Last updated: February 20, 2026
What is RYTHMOL SR?
RYTHMOL SR (disopyramide phosphate extended-release) is an antiarrhythmic agent used to treat ventricular arrhythmias and atrial fibrillation. It is a class IA sodium channel blocker that stabilizes cardiac electrical activity. Approved in various markets, including the United States and Europe, RYTHMOL SR competes within the antiarrhythmic drug space targeting atrial and ventricular rhythm disorders.
Market Overview
Current Market Size
The global antiarrhythmic drugs market was valued at approximately $3.2 billion in 2022, growing at a compound annual growth rate (CAGR) of around 4.5%. Within this, the segment for sustained-release formulations like RYTHMOL SR accounts for an estimated 8-10%, driven by demand for once-daily dosing options.
Key Competitors
- Amiodarone: Largest share, >50%
- Flecainide: ~8%
- Propafenone: ~7%
- Dronedarone: ~4%
- Others: Including disopyramide products, with RYTHMOL SR holding niche or branded segments
Regulatory and Prescribing Trends
Prescriptions for antiarrhythmics increased by 2-3% annually over the past five years, driven by aging populations and heightened arrhythmia detection. However, safety concerns, especially for drugs like amiodarone with many contraindications and side effects, have driven demand for alternative formulations like RYTHMOL SR.
Patents and Market Exclusivity
Disopyramide's original patents expired in the early 2000s, but extended formulations like RYTHMOL SR may have exclusive rights until 2025-2030, depending on jurisdiction and patent life extensions.
Price Analysis
Current Wholesale and Retail Pricing
- Average wholesale price (AWP): $5.50 per 100 mg tablet
- Average retail price: $8.00 per tablet
- Monthly therapy (assuming 300 mg daily): 30 tablets, costing approximately $240 retail
Pricing Compared with Competitors
| Drug |
Typical Dose |
Monthly Cost |
Market Share |
| RYTHMOL SR |
300 mg/day |
$240 |
Niche (~10%) |
| Amiodarone |
Variable |
$150–$200 |
>50% |
| Flecainide |
50–100 mg BID |
$100–$150 |
~8% |
| Propafenone |
300 mg TID |
$120–$180 |
~7% |
RHYTHMOL SR's pricing reflects its formulation and brand positioning. It often commands a premium over generics, especially where branded preference persists.
Market Projection (2023–2030)
Assumptions
- Stable patent protection until 2025, then increased generics
- Annual prescription growth of 3%, driven by aging populations and increased arrhythmia diagnosis
- A shift toward personalized medicine reduces overall antiarrhythmic market growth to 3% from previous 4.5%
- Introduction of value-based pricing models and payer negotiations
Revenue Projection
| Year |
Estimated Market Size (USD billion) |
RYTHMOL SR Market Share |
Estimated Revenue (USD billion) |
| 2023 |
3.4 |
10% |
0.34 |
| 2025 |
3.65 |
10% |
0.365 |
| 2027 |
4.00 |
12% |
0.48 |
| 2030 |
4.36 |
12% |
0.52 |
Post-2025, generic penetration could reduce RYTHMOL SR's share to 8%, with prices declining accordingly.
Price Discount Scenarios
- Conservative (No price change): Marginal price drops by 10–15% post-patent expiry.
- Aggressive (Pricing Competition): 25%–35% price reductions as generics enter.
Opportunities and Risks
-
Opportunities:
- Growing prevalence of atrial fibrillation and arrhythmias breeds continued demand
- Improved formulations enhancing patient adherence
- Potential expansion into emerging markets
-
Risks:
- Patent expiration leading to generic erosion
- Competition from newer agents with better safety profiles
- Regulatory restrictions or safety concerns, notably related to side effects
Key Takeaways
- RYTHMOL SR holds a niche position within an $3.2 billion global market, projected to grow at 3% annually.
- Its higher pricing is justified by extended-release formulation and branded status, but generic competition threatens margins post-2025.
- Market growth factors include increasing arrhythmia prevalence; price erosion stems from patent expiries and generics.
- Strategies should focus on patent protection, geographic expansion, and differentiation through clinical data.
FAQs
-
When will generic versions of RYTHMOL SR enter the market?
Likely around 2025-2027, depending on patent expiry and regulatory approvals.
-
What are the main competitors for RYTHMOL SR?
Amiodarone, flecainide, propafenone, and other branded or generic disopyramide formulations.
-
How does pricing of RYTHMOL SR compare globally?
Prices in the U.S. average $8 per tablet retail, while in Europe, prices vary based on reimbursement policies and generic availability.
-
What factors influence future demand for RYTHMOL SR?
Demographic shifts, clinical guidelines favoring certain agents, patent protection, and drug efficacy/safety profiles.
-
What is the impact of regulatory changes on RYTHMOL SR?
Stricter safety regulations could limit usage or require additional clinical trials, affecting profitability and market share.
References
- MarketsandMarkets. (2023). Antiarrhythmic Drugs Market. Retrieved from https://www.marketsandmarkets.com
- IQVIA. (2022). Global Prescription Drug Data.
- FDA. (2022). Drug Approvals and Patent Data.
- European Medicines Agency. (2023). Market Authorizations for Antiarrhythmic Drugs.
- Smith, J. (2022). Antiarrhythmic Drugs - Market Trends and Future Outlook. Journal of Cardiology.
